VIR
Vir Biotechnology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.21
+2.51%Year over year
Reported trailing growth
- Revenue
- +1495.9%
- EBITDA
- +51.9%
- EBIT
- +53.2%
- EPS
- +53.8%
- Free cash flow
- +57.4%
- Operating cash flow
- +55.7%
Forward estimates
Based on analyst estimates
- Revenue
- -79.2%
- EBITDA
- -50.5%
- EPS
- -32.3%
Three-year CAGR
- Revenue
- -65.1%
- EBITDA
- +10.3%
- EBIT
- +10.6%
- Net income
- +16.1%
- EPS
- +17.5%
- Free cash flow
- +12.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026